《大行报告》瑞信升石药(01093.HK)目标价至11.5元 管理层料今年收入双位数增长
瑞信发表报告表示,石药(01093.HK)去年度收入按年升12.8%至249亿元人民币,低於该行预期;纯利按年升38.9%至52亿元人民币,则胜预期。公司管理层透露,预计今年度销售录双位数增长,以及未来两年斥资50亿元人民币於业务发展上;公司持续投资於产品研发上,料今年度有两种产品获批。
该行轻微上调石药2021至2022年度销售预测0.3%及4.7%,盈利预测分别升18%及20%,目标价由11元升至11.5元,维持「跑赢大市」评级。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.